In China, the incidence of primary liver cancer ranked fifth among that of malignant tumors in 2020, with 410,000 new cases, including 303,000 cases in men; the mortality rate of the cancer ranked second with 391,000 deaths in 2020, a mortality rate of 17.2/100,000 of the total population. From 2016 to 2020, global average annual incidence of primary liver cancer was 995,000 cases, with Asia 732,000 cases, accounting for 73.6%, and China 423,000 cases, accounting for 42.5%. The high incidence of liver cancer in China is highly correlated with the fact that China is a country with high prevalence of hepatitis B, environmental pollution, and some spirits-addicted residents.

Liver cancer is a common malignant tumor in China. Liver cancer starts insidiously but progresses rapidly, and by the time it is detected, it is often at an advanced stage, making the treatment of surgery ineffective. Moreover, radiotherapy is of little use in treating liver cancer. Therefore, targeted drug therapy becomes the standard treatment for patients with advanced liver cancer. Sorafenib is the world’s first multi-targeted, multi-kinase inhibitor for the treatment of liver cancer. It can directly suppress tumor growth by inhibiting RAF/MEK/ERK signaling pathway, and indirectly suppress tumor growth by blocking the formation of tumor neovascularization through inhibiting VEGFR and PDGFR. Therefore, it is the first-line drug used for the treatment of advanced primary liver cancer.

Sorafenib is a multi-kinase inhibitor originally developed by Bayer AG with the trade name of Nexavar^®. Sorafenib was approved for marketing by the FDA of U.S. in December 2005 and approved by China in August 2006. In 2017, Bayer’s sorafenib was included in the category B of China’s national medical insurance catalog after a negotiated price reduction of about 70%, and the price after inclusion in medical insurance is about CNY200 (approximately USD30.8) per tablet. From 2018 to 2021, Bayer AG continues to reduce the price of sorafenib in the Chinese market.

According to CRI’s market research, the sales value of China’s sorafenib market continued to grow from 2016 to 2019. In 2020, the sales value declined to approximately USD406 million due to COVID-19, but the CAGR from 2016 to 2020 was still up to 22.3%.

As of August 2021, besides Bayer’s sorafenib product, only generic versions of Jiangxi Shanxiang Pharmaceutical and Chongqing Yaoyou Pharmaceutical have been officially marketed in the Chinese market. Some other companies such as Yabao Pharmaceutical Group and CSPC Ouyi Pharmaceutical have filed applications for the marketing of generic sorafenib drugs. In September 2020, The China National Intellectual Property Administration issued an invalidation request review decision (No. 46292), declaring that Bayer’s patent CN200680007187.1 for sorafenib mesylate in China was invalid. The invalidation petitioner was Chongqing Yaoyou Pharmaceutical. With the invalidation of Bayer’s patent applications related to sorafenib, more generic sorafenib drugs from local Chinese pharmaceutical companies will be launched in China.

For Bayer, as more generic drugs are approved and marketed, the market share of Nexavar in China will gradually decline. Bayer is expected to stop the decline of Nexavar’s market share through measures such as price cuts.

CRI expects that from 2021 to 2025, the average sales price of sorafenib in China will decline due to fierce competition while both sales volume and value will continue to rise.

Topics Covered:

• Impact of COVID-19 on China’s Sorafenib Market
• Development Environment of Sorafenib in China
• Sales Volume of Sorafenib in China
• Sales Volume and Value of Sorafenib in China by Region
• Major Sorafenib Manufacturers in China and Their Market Shares
• Sales Price of Sorafenib in China
• Prospects of China’s Sorafenib Market, 2021-2025

Related reports:

Investigation Report on Chinese Sorafenib Market, 2018-2022

The post Research Report on China’s Sorafenib Market, 2021-2025 first appeared on CRI Report.

Investigation Report on Chinese Sorafenib Market, 2018-2022

The post Sample of Investigation Report on Chinese Sorafenib Market, 2018-2022 first appeared on CRI Report.

Sorafenib is mainly used to treat inoperable advanced renal cell carcinoma and inoperable or metastasized primary hepatocellular carcinoma. Sorafenib was jointly developed by Bayer and ONYX. In 2006, the drug was approved to be imported to China. In 2008, it entered China after the liver cancer indication was approved by the CFDA.

Liver cancer is the sixth most common cancer in the world and the second leading cause of cancer-related death. It is estimated that over 800 thousand cases of liver cancer are diagnosed worldwide (more than 400 thousand cases in China) every year with a continuous increase in incidence. In 2012, around 746 thousand people died of liver cancer, including 383 thousand deaths in China. As the most effective targeted drug for liver cancer, Sorafenib brings hope to numerous tumor patients.

Research Report on China’s Sorafenib Market, 2021-2025

According to CRI, Sorafenib has been growing since it entered China. In 2017, its sales value in China was about CNY 195 million. Currently, Sorafenib legally sold in China are all Bayer’s products.

According to CRI, cancer incidence continues to rise in China because of aggravating environmental pollution and changing lifestyle. Therefore, there will be a great demand for Sorafenib. After several links of circulation, Bayer’s Sorafenib is so high-priced that many low-income patients cannot afford it. Some patients choose to purchase Sorafenib produced by Indian enterprises such as NATCO and smuggled to China because the price is only 2%-3% of that of Bayer’s Sorafenib. Some Chinese enterprises has also started the development of generic drugs.

It is possible that China-made Sorafenib will appear on the market after 2022.

Topics Covered:

-Sales of Sorafenib in China

-Prices of Sorafenib in China

-Sales of Sorafenib in China by region

-Sales of India-made Sorafenib in China

-Prospects of Chinese Sorafenib market

The post Investigation Report on Chinese Sorafenib Market, 2018-2022 first appeared on CRI Report.